Context Therapeutics (NASDAQ:CNTX) stock is rising higher on Friday thanks to results from a Phase 0 clinical trial.
That trial saw the company treating 10 women suffering from breast cancer in its early stages. The goal of the trial was to determine the effectiveness of onapristone extended release in treating these women’s tumors.
According to results from the study, no patient received a Complete Cell Cycle Arrest. However, six of them saw tumor Ki-67 expression decrease, one remained stable and three increased. In addition to that, there was a move toward more endocrine-sensitive disease was detected. That implies a possible increase in tumor treatment with anti-estrogen therapy.
Martin Lehr, CEO of Context Therapeutics, said the following in the press release boosting CNTX stock higher today.
“ONA-XR is being evaluated in four investigator-sponsored clinical trials in hormone-driven breast, ovarian and endometrial cancers. This readout is the first for the novel PR antagonist, and the results are encouraging early evidence of the potential of ONA-XR to offer a new therapeutic option for hormone-dependent cancers. We look forward to data updates from three other ONA-XR trials in 2022.”
Following news of the clinical trial results, CNTX stock is experiencing heavy trading today. That has some 9 million shares on the move, as compared to its daily average trading volume of about 5.9 million shares.
CNTX stock is up 9% as of Friday morning and is up 33.7% since the start of the year.
Investors on the lookout for more recent stock market news don’t have to search far.
InvestorPlace has all the latest stock news that traders need to know about. A few examples include this morning’s biggest pre-market stock movers, as well as the latest on Digital World Acquisition (NASDAQ:DWAC) and CVS Health (NYSE:CVS) shares. You can find all of that info by checking out the links below!
More Stock Market News for Friday
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed